Edwards Lifesciences Corporation (NYSE: EW) is a Healthcare company (Medical - Devices) with a market capitalization of $61.6B. The Maz Rating grades it against the other companies in its sector.
Edwards Lifesciences Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $107.11, Edwards Lifesciences Corporation trades at 60.5x trailing earnings, 9.2x sales and 5.7x book value, with an EV/EBITDA of 36.9. Over the last twelve months it generated about $6.7B of revenue and $1.0B of net income. It runs a gross margin of 78.1%, an operating margin of 24.9% and a net margin of 15.3%. It shows return on equity of 9.7%, return on invested capital of 9.1% and a free cash flow yield of 2.3%. On the balance sheet: a debt-to-equity ratio of 0.06 and a current ratio of 4.60. Over the past 52 weeks the share price ranged from $74.66 to $108.00, with a beta of 0.83.
Edwards Lifesciences Corporation does not currently pay a dividend.
49 Wall Street analyst ratings cover the stock: 34 Buy and 15 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Edwards Lifesciences Corporation (EW) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 1.15% / 30% · (Cash+Inv) / Mkt Cap (36m) 9.39% / 30% · Interest income / Revenue 2.13% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 1.15% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 8.88% / 33% · Receivables / Mkt Cap (36m) 1.79% / 49% · Interest income / Revenue 2.13% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 1.15% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 8.88% / 33.33% · Receivables / Mkt Cap (24m) 1.79% / 33.33% · Interest income / Revenue 2.13% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 4.44% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 30.5% / 33.33% · Receivables / Avg Assets (4Q) 6.87% / 33.33% · Interest income / Revenue 2.13% / 5% | Pass |
| FTSE | Debt / Total Assets 4.23% / 33.33% · (Cash+ST Inv) / Total Assets 32.8% / 33.33% · (Cash+Recv) / Total Assets 39.5% / 33.33% · Interest income / Revenue 2.13% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Edwards Lifesciences Corporation (EW) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
Yes. Edwards Lifesciences Corporation is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 2.13% of each dividend: Edwards Lifesciences Corporation's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.